Hydrothermal synthesis and preliminary cytotoxicity assessment of gadolinium borate nanoparticles for neutron capture therapy
Source abstract
Abstract
Neutron capture therapy, such as boron neutron capture therapy (BNCT) and gadolinium neutron capture therapy (GdNCT), has been attracting much attention as a next-generation radiotherapy. Nanoparticles containing both boron and gadolinium can accumulate in tumours because of the enhanced permeability and retention (EPR) effect, thereby simultaneously rendering the benefits of BNCT and GdNCT. In this study, we obtained flake-shaped gadolinium borate (GdBO3) nanoparticles, approximately 80 nm in length and 20 nm in width, by hydrothermal treatment of a solution containing gadolinium chloride, boric acid, and polyethylene glycol at 220 °C for 24 h. These GdBO3 nanoparticles did not show any serious cytotoxic effect against human umbilical vein endothelial cells over a concentration range of 3–300 µg·mL–1. The results suggest that GdBO3 nanoparticles can accumulate in tumours because of the EPR effect and can function as boron and gadolinium nanocarriers for neutron capture therapy. However, further in vitro and in vivo studies are needed for the application of these nanoparticles in neutron capture therapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Boron Compounds in Chemistry · Boron and Carbon Nanomaterials Research · Nuclear Physics and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Achilli C, Grandi S, Ciana A et al (2014) Biocompatibility of functionalized boron phosphate (BPO4) nanoparticles for boron neutron capture therapy (BNCT) application. Nanomedicine 10:589–597. https://doi.org/10.1016/j.nano.2013.10.00310.1016/j.nano.2013.10.003 ↗
2. Ahmad MW, Xu W, Kim SJ et al (2015) Potential dual imaging nanoparticle: Gd2O3 nanoparticle. Sci Rep 5:8549. https://doi.org/10.1038/srep0854910.1038/srep08549 ↗
3. Akine Y, Tokita N, Tokuuye K et al (1993) Suppression of rabbit VX-2 subcutaneous tumor growth by gadolinium neutron capture therapy. Jpn J Cancer Res 84:841–843. https://doi.org/10.1111/j.1349-7006.1993.tb02055.x10.1111/j.1349-7006.1993.tb02055.x ↗
4. Arvanitis CD, Ferraro GB, Jain RK (2020) The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat Rev Cancer 20:26–41. https://doi.org/10.1038/s41568-019-0205-x10.1038/s41568-019-0205-x ↗
5. Barth RF, Coderre JA, Vicente MG et al (2005) Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 11:3987–4002. https://doi.org/10.1158/1078-0432.CCR-05-003510.1158/1078-0432.CCR-05-0035 ↗
6. Barth RF, Mi P, Yang W (2018) Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (lond) 38:35. https://doi.org/10.1186/s40880-018-0299-710.1186/s40880-018-0299-7 ↗
7. Barth RF, Vicente MGH, Harling OK et al (2012) Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol 7:146. https://doi.org/10.1186/1748-717X-7-14610.1186/1748-717X-7-146 ↗
8. Bridot JL, Faure AC, Laurent S et al (2007) Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem Soc 129:5076–5084. https://doi.org/10.1021/ja068356j10.1021/ja068356j ↗
9. Cao Y, Gong Y, Liu LL et al (2017) The use of human umbilical vein endothelial cells (HUVECs) as an in vitro model to assess the toxicity of nanoparticles to endothelium: a review. J Appl Toxicol 37:1359–1369. https://doi.org/10.1002/jat.347010.1002/jat.3470 ↗
10. Carlsson J, Sjöberg S, Larsson BS (1992) Present status of boron neutron capture therapy. Acta Oncol 31:803–813. https://doi.org/10.3109/0284186920908971210.3109/02841869209089712 ↗
11. Ciofani G, Raffa V, Menciassi A et al (2009) Folate functionalized boron nitride nanotubes and their selective uptake by glioblastoma multiforme cells: implications for their use as boron carriers in clinical boron neutron capture therapy. Nanoscale Res Lett 4:113–121. https://doi.org/10.1007/s11671-008-9210-910.1007/s11671-008-9210-9 ↗
12. Coderre JA, Morris GM (1999) The radiation biology of boron neutron capture therapy. Radiat Res 151:1–18. https://doi.org/10.2307/357974210.2307/3579742 ↗
13. De Stasio G, Casalbore P, Pallini R et al. (2001) Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res 61:4272–4277. https://cancerres.aacrjournals.org/content/61/10/4272.full-text.pdf. Accessed 17 Mar 2021
14. Dong Y, Meng F (2020) Effect of polyethylene glycol on crystal growth and photocatalytic activity of anatase TiO2 single crystals. RSC Adv 10:12511–12518. https://doi.org/10.1039/D0RA01796E10.1039/D0RA01796E ↗
15. Fukumori Y, Ichikawa H (2006) Nanoparticles for cancer therapy and diagnosis. Adv Powder Technol 17:1–28. https://doi.org/10.1163/15685520677512349410.1163/156855206775123494 ↗
16. Grandi S, Spinella A, Tomasi C et al (2012) Synthesis and characterisation of functionalized borosilicate nanoparticles for boron neutron capture therapy applications. J Sol-Gel Sci Technol 64:358–366. https://doi.org/10.1007/s10971-012-2865-910.1007/s10971-012-2865-9 ↗
17. Hemmer E, Yamano T, Kishimoto H et al (2013) Cytotoxic aspects of gadolinium oxide nanostructures for up-conversion and NIR bioimaging. Acta Biomater 9:4734–4743. https://doi.org/10.1016/j.actbio.2012.08.04510.1016/j.actbio.2012.08.045 ↗
18. Ho SL, Choi G, Yue H et al (2020) In vivo neutron capture therapy of cancer using ultrasmall gadolinium oxide nanoparticles with cancer-targeting ability. RSC Adv 10:865–874. https://doi.org/10.1039/C9RA08961F10.1039/C9RA08961F ↗
19. Icten O, Kose DA, Matissek SJ et al (2018) Gadolinium borate and iron oxide bioconjugates: nanocomposites of next generation with multifunctional applications. Mater Sci Eng C Mater Biol Appl 92:317–328. https://doi.org/10.1016/j.msec.2018.06.04210.1016/j.msec.2018.06.042 ↗
20. Icten O, Kose DA, Zumreoglu-Karan B (2017) Fabrication and characterization of magnetite-gadolinium borate nanocomposites. J Alloys Compd 726:437–444. https://doi.org/10.1016/j.jallcom.2017.07.27710.1016/j.jallcom.2017.07.277 ↗
21. Kang H, Rho S, Stiles WR et al (2020) Size-dependent EPR effect of polymeric nanoparticles on tumor targeting. Adv Healthc Mater 9:e1901223. https://doi.org/10.1002/adhm.20190122310.1002/adhm.201901223 ↗
22. Karlsson HL, Gustafsson J, Cronholm P, Möller L (2009) Size-dependent toxicity of metal oxide particles - a comparison between nano- and micrometer size. Toxicol Lett 188:112–118. https://doi.org/10.1016/j.toxlet.2009.03.01410.1016/j.toxlet.2009.03.014 ↗
23. Kim T, Kang S (2005) Hydrothermal synthesis and photoluminescence properties of nano-crystalline GdBO3:Eu3+ phosphor. Mater Res Bull 40:1945–1954. https://doi.org/10.1016/j.materresbull.2005.06.00110.1016/j.materresbull.2005.06.001 ↗
24. Leng Z, Liu Y, Zhang N et al (2015a) Controlled synthesis and luminescent properties of different morphologies GdBO3:Eu3+ phosphors self-assembled of nanoparticles. Colloids Surf A Physicochem Eng Aspects 472:109–116. https://doi.org/10.1016/j.colsurfa.2015.02.04610.1016/j.colsurfa.2015.02.046 ↗
25. Leng Z, Zhang N, Liu Y et al (2015b) Controlled synthesis of different multilayer architectures of GdBO3:Eu3+ phosphors and shape-dependent luminescence properties. Appl Surf Sci 330:270–279. https://doi.org/10.1016/j.apsusc.2015.01.04610.1016/j.apsusc.2015.01.046 ↗
26. Li L, Dai K, Li J et al (2021) A boron-10 nitride nanosheet for combinational boron neutron capture therapy and chemotherapy of tumor. Biomaterials 268:120587. https://doi.org/10.1016/j.biomaterials.2020.12058710.1016/j.biomaterials.2020.120587 ↗
27. Li Z, Zeng Y, Qian HX et al (2012) Facile synthesis of GdBO3 spindle assemblies and microdisks as versatile host matrices for lanthanide doping. Cryst Eng Commun 14:3959–3964. https://doi.org/10.1039/C2CE06596G10.1039/C2CE06596G ↗
28. Mortensen MW, Sørensen PG, Björkdahl O et al (2006) Preparation and characterization of boron carbide nanoparticles for use as a novel agent in T cell-guided boron neutron capture therapy. Appl Radiat Isot 64:315–324. https://doi.org/10.1016/j.apradiso.2005.08.00310.1016/j.apradiso.2005.08.003 ↗
29. Nel A, Ruoslahti E, Meng H (2017) New insights into “permeability” as in the enhanced permeability and retention effect of cancer nanotherapeutics. ACS Nano 11:9567–9569. https://doi.org/10.1021/acsnano.7b0721410.1021/acsnano.7b07214 ↗
30. Nichols JW, Bae YH (2014) EPR: evidence and fallacy. J Control Release 190:451–464. https://doi.org/10.1016/j.jconrel.2014.03.05710.1016/j.jconrel.2014.03.057 ↗
31. Park JY, Baek MJ, Choi ES et al (2009) Paramagnetic ultrasmall gadolinium oxide nanoparticles as advanced T1 MRI contrast agent: account for large longitudinal relaxivity, optimal particle diameter, and in vivo T1 MR images. ACS Nano 3:3663–3669. https://doi.org/10.1021/nn900761s10.1021/nn900761s ↗
32. Park JY, Chang Y, Lee GH (2015) Multi-modal imaging and cancer therapy using lanthanide oxide nanoparticles: current status and perspectives. Curr Med Chem 22:569–581. https://doi.org/10.2174/092986732266614112816284310.2174/0929867322666141128162843 ↗
33. Pulagam KR, Gona KB, Gómez-Vallejo V et al (2019) Gold nanoparticles as boron carriers for boron neutron capture therapy: synthesis, radiolabelling and in vivo evaluation. Molecules 24:3609. https://doi.org/10.3390/molecules2419360910.3390/molecules24193609 ↗
34. Salt C, Lennox AJ, Takagaki M et al (2004) Boron and gadolinium neutron capture therapy. Russ Chem Bull 53:1871–1888. https://doi.org/10.1007/s11172-005-0045-610.1007/s11172-005-0045-6 ↗
35. Setyawati MI, Khoo PKS, Eng BH et al (2013) Cytotoxic and genotoxic characterization of titanium dioxide, gadolinium oxide, and poly(lactic-co-glycolic acid) nanoparticles in human fibroblasts. J Biomed Mater Res A 101:633–640. https://doi.org/10.1002/jbm.a.3436310.1002/jbm.a.34363 ↗
36. Shibata M, Kanetaka H, Furuya M et al (2021) Cytotoxicity evaluation of iron nitride nanoparticles for biomedical applications. J Biomed Mater Res A. https://doi.org/10.1002/jbm.a.3717110.1002/jbm.a.37171 ↗
37. Shih JL, Brugger RM (1992) Gadolinium as a neutron capture therapy agent. Med Phys 19:733–744. https://doi.org/10.1118/1.59681710.1118/1.596817 ↗
38. Tiwary S, Morales JE, Kwiatkowski SC et al (2018) Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Sci Rep 8:8267. https://doi.org/10.1038/s41598-018-26636-610.1038/s41598-018-26636-6 ↗
39. Torresan V, Guadagnini A, Badocco D et al (2021) Biocompatible iron–boron nanoparticles designed for neutron capture therapy guided by magnetic resonance imaging. Adv Healthc Mater 10:e2001632. https://doi.org/10.1002/adhm.20200163210.1002/adhm.202001632 ↗
40. Wu X, Tan Y, Mao H et al (2010) Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int J Nanomed 5:385–399. https://doi.org/10.2147/ijn.s1045810.2147/ijn.s10458 ↗
41. Xu Z, Li C, Yang D et al (2010) Self-templated and self-assembled synthesis of Nano/microstructures of Gd-based rare-earth compounds: morphology control, magnetic and luminescence properties. Phys Chem Chem Phys 12:11315–11324. https://doi.org/10.1039/C0CP00169D10.1039/C0CP00169D ↗
42. Yang L, Zhou L, Huang Y et al (2011) Controlled synthesis of different morphologies of GdBO3:Eu3+ crystals and shape-dependent luminescence properties. Mater Chem Phys 131:477–484. https://doi.org/10.1016/j.matchemphys.2011.10.00710.1016/j.matchemphys.2011.10.007 ↗
43. Zhan H, Yang X, Wang C et al (2012) Multiple nucleation and crystal growth of barium titanate. Cryst Growth Des 12:1247–1253. https://doi.org/10.1021/cg201259u10.1021/cg201259u ↗
44. Zhu Y, Liang Y, Liu S et al (2016) Morphology evolution of Gd0.99Eu0.01BO3 phosphors synthesized by hydrothermal method with Gd0.99Eu0.01(OH)3 nanorods as sacrificial precursors. J Alloys Compd 685:848–859. https://doi.org/10.1016/j.jallcom.2016.06.21510.1016/j.jallcom.2016.06.215 ↗